Alphatec Secures Exclusive Rights to OsteoAdapt® Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATEC?
Source: Newsfilter
Alphatec Holdings Inc (ATEC) saw a significant decline of 19.38% as it crossed below its 5-day SMA, reflecting investor concerns following recent news.
The company has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft. This partnership is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure. OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market.
Despite the recent stock decline, the strategic partnership positions Alphatec to capitalize on a significant market opportunity in the U.S. spine surgery market, which exceeds $10 billion annually. The ongoing clinical trials and the expected commercialization of OsteoAdapt could drive future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATEC
Wall Street analysts forecast ATEC stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 13.620
Low
20.00
Averages
24.33
High
28.00
Current: 13.620
Low
20.00
Averages
24.33
High
28.00
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphatec Holdings Shows Strong Growth Potential
- Strong Financial Performance: Alphatec Holdings, Inc. reported a preliminary total revenue increase of approximately 25% for fiscal year 2025, with surgical revenue growth of 26%, surgical volume growth of 24%, and a 2% increase in average revenue per procedure, indicating robust market performance and growth potential.
- Market Expectation Adjustment: TD Cowen lowered the price target for Alphatec from $27 to $20 while maintaining a Buy rating, suggesting that the market has not fully recognized the company's growth vectors, indicating potential upside in future estimates.
- Positive Outlook: The company expects total revenue of $890 million for fiscal year 2026, demonstrating ongoing growth momentum and market confidence, further solidifying its position in the spinal fusion technology sector.
- Competitive Environment Analysis: While Alphatec shows strong growth potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diversified view of investment opportunities in the market.
See More
Penn Capital Increases Stake in ACM Research, Inc.
- New Investment Dynamics: Penn Capital Management established a new position in ACM Research during Q4 2025, acquiring 435,843 shares, with a quarter-end value increase of $17.21 million, reflecting strong confidence in the semiconductor equipment market.
- Asset Allocation Shift: This new position accounts for 1.37% of Penn Capital's 13F reportable assets under management, indicating a strategic focus on the semiconductor industry, particularly in the context of AI and advanced chip manufacturing.
- Outstanding Stock Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, up 171.5% over the past year, outperforming the S&P 500 by 157.6 percentage points, showcasing market recognition of its growth potential.
- Industry Outlook Analysis: ACM Research specializes in providing advanced cleaning and plating equipment for semiconductor manufacturing, and with the surge in AI processor demand, the company’s revenue from the Chinese market is significant, facing dual challenges of self-sufficiency and export controls.
See More
Penn Capital Initiates Position in ACM Research with $17.21 Million Investment
- New Investment Position: Penn Capital initiated a position in ACM Research during Q4 2025 by purchasing 435,843 shares for an estimated $17.21 million, reflecting confidence in the semiconductor sector.
- Value Appreciation: As of December 31, 2025, the position's quarter-end value stood at $17.21 million, indicating a positive impact from both the share purchase and price movements, showcasing market recognition of ACM Research.
- Strong Market Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, representing a 171.5% increase over the previous year, generating 157.6 percentage points of alpha compared to the S&P 500, highlighting its robust performance in the semiconductor equipment market.
- Promising Industry Outlook: ACM Research focuses on advanced wafer cleaning and plating equipment, and with the rising demand for AI processors, its products are becoming increasingly vital in semiconductor manufacturing, positioning the company for greater market share amidst China's push for semiconductor self-sufficiency.
See More
U.S. Stock Futures Rise Slightly Amid Earnings Beat
- Earnings Beat: The company reported quarterly earnings of $0.81 per share, surpassing the analyst consensus estimate of $0.77 per share, indicating improved profitability that may boost investor confidence.
- Sales Growth: Quarterly sales reached $14.438 billion, exceeding the analyst consensus estimate of $13.943 billion, demonstrating the company's competitive position and strong product demand in the market.
- Stock Price Movement: Despite the strong earnings report, HP shares dipped 5.2% to $17.25 in pre-market trading, reflecting cautious market sentiment regarding future prospects.
- Market Dynamics: U.S. stock futures rose slightly on Wednesday, with Dow futures gaining around 0.1%, indicating a generally optimistic investor sentiment towards the overall market, though individual stock performances warrant close attention.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
Alphatec Holdings Reports Strong Q4 2025 Earnings with 20% Revenue Growth
- Significant Revenue Growth: Alphatec reported Q4 2025 revenue of $213 million, reflecting a 20% year-over-year increase, with surgical revenue at $190 million, underscoring the company's strong performance in the spine surgery sector and reinforcing its market leadership.
- Strong EBITDA Performance: Adjusted EBITDA reached $33 million, up 61% year-over-year, with a 16% adjusted EBITDA margin, indicating ongoing improvements in cost control and operational efficiency, which will enhance future profitability.
- New Product Launches: The company introduced several new products, including a bone mineral density test and 3D-printed implants, expected to drive future revenue growth and strengthen its competitive position in the medical device market, particularly in complex procedures.
- Optimistic 2026 Outlook: Management projects a 17% revenue growth for 2026, reaching approximately $890 million, with an increased adjusted EBITDA target of $134 million, demonstrating confidence in sustained growth and profitability while planning investments in sales force expansion and technology integration.
See More
Alphatec Holdings Shows Strong Growth Potential
- Strong Financial Performance: Alphatec Holdings, Inc. reported a preliminary total revenue increase of approximately 25% for fiscal year 2025, with surgical revenue growth of 26%, surgical volume growth of 24%, and a 2% increase in average revenue per procedure, indicating robust market performance and growth potential.
- Market Expectation Adjustment: TD Cowen lowered the price target for Alphatec from $27 to $20 while maintaining a Buy rating, suggesting that the market has not fully recognized the company's growth vectors, indicating potential upside in future estimates.
- Positive Outlook: The company expects total revenue of $890 million for fiscal year 2026, demonstrating ongoing growth momentum and market confidence, further solidifying its position in the spinal fusion technology sector.
- Competitive Environment Analysis: While Alphatec shows strong growth potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diversified view of investment opportunities in the market.
See More
Penn Capital Increases Stake in ACM Research, Inc.
- New Investment Dynamics: Penn Capital Management established a new position in ACM Research during Q4 2025, acquiring 435,843 shares, with a quarter-end value increase of $17.21 million, reflecting strong confidence in the semiconductor equipment market.
- Asset Allocation Shift: This new position accounts for 1.37% of Penn Capital's 13F reportable assets under management, indicating a strategic focus on the semiconductor industry, particularly in the context of AI and advanced chip manufacturing.
- Outstanding Stock Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, up 171.5% over the past year, outperforming the S&P 500 by 157.6 percentage points, showcasing market recognition of its growth potential.
- Industry Outlook Analysis: ACM Research specializes in providing advanced cleaning and plating equipment for semiconductor manufacturing, and with the surge in AI processor demand, the company’s revenue from the Chinese market is significant, facing dual challenges of self-sufficiency and export controls.
See More
Penn Capital Initiates Position in ACM Research with $17.21 Million Investment
- New Investment Position: Penn Capital initiated a position in ACM Research during Q4 2025 by purchasing 435,843 shares for an estimated $17.21 million, reflecting confidence in the semiconductor sector.
- Value Appreciation: As of December 31, 2025, the position's quarter-end value stood at $17.21 million, indicating a positive impact from both the share purchase and price movements, showcasing market recognition of ACM Research.
- Strong Market Performance: As of February 6, 2026, ACM Research shares were priced at $62.48, representing a 171.5% increase over the previous year, generating 157.6 percentage points of alpha compared to the S&P 500, highlighting its robust performance in the semiconductor equipment market.
- Promising Industry Outlook: ACM Research focuses on advanced wafer cleaning and plating equipment, and with the rising demand for AI processors, its products are becoming increasingly vital in semiconductor manufacturing, positioning the company for greater market share amidst China's push for semiconductor self-sufficiency.
See More
U.S. Stock Futures Rise Slightly Amid Earnings Beat
- Earnings Beat: The company reported quarterly earnings of $0.81 per share, surpassing the analyst consensus estimate of $0.77 per share, indicating improved profitability that may boost investor confidence.
- Sales Growth: Quarterly sales reached $14.438 billion, exceeding the analyst consensus estimate of $13.943 billion, demonstrating the company's competitive position and strong product demand in the market.
- Stock Price Movement: Despite the strong earnings report, HP shares dipped 5.2% to $17.25 in pre-market trading, reflecting cautious market sentiment regarding future prospects.
- Market Dynamics: U.S. stock futures rose slightly on Wednesday, with Dow futures gaining around 0.1%, indicating a generally optimistic investor sentiment towards the overall market, though individual stock performances warrant close attention.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
Alphatec Holdings Reports Strong Q4 2025 Earnings with 20% Revenue Growth
- Significant Revenue Growth: Alphatec reported Q4 2025 revenue of $213 million, reflecting a 20% year-over-year increase, with surgical revenue at $190 million, underscoring the company's strong performance in the spine surgery sector and reinforcing its market leadership.
- Strong EBITDA Performance: Adjusted EBITDA reached $33 million, up 61% year-over-year, with a 16% adjusted EBITDA margin, indicating ongoing improvements in cost control and operational efficiency, which will enhance future profitability.
- New Product Launches: The company introduced several new products, including a bone mineral density test and 3D-printed implants, expected to drive future revenue growth and strengthen its competitive position in the medical device market, particularly in complex procedures.
- Optimistic 2026 Outlook: Management projects a 17% revenue growth for 2026, reaching approximately $890 million, with an increased adjusted EBITDA target of $134 million, demonstrating confidence in sustained growth and profitability while planning investments in sales force expansion and technology integration.
See More
